Future of targeted therapy for gastrointestinal cancer: Claudin 18.2

• 作者: Qian Niu Jiamin Liu Xiaoxiao Luo Beibei Su Xianglin Yuan
• 来源期刊: 肿瘤学与转化医学（英文版）
• 年，卷（期）: 2021,（3）
• 页码范围: 102-107
• 页数: 6页
• 语种: 英文
• DOI: 10.1007/s10330-020-0470-0

摘要

The treatment of gastrointestinal cancer has always been a crucial research area, and targeted therapy has been receiving increasing attention. At present, the effect of targeted therapy is unsatisfactory for gastric cancer. Thus, the discovery of new targets is crucial. Claudin 18.2 (CLDN18.2), a member of the claudin family, belongs to the tight junction protein family that controls the flow of molecules between cell layers. CLDN18.2 expression has been discussed in many studies. In recent years, there have been many studies on targeted therapy with CLDN18.2-ideal monoclonal antibody 362. Furthermore, CLDN18.2-specific chimeric antigen receptor T therapy has been used for CLDN18.2-positive tumors, such as gastric and pancreatic cancers. Considerable research has been focused on CLDN18.2. CLDN18.2, a newly discovered marker for precise targeted therapy of gastric cancer, could offer new hope for the treatment of gastric cancer.